Evidence map›Paper›PMID 29076000›Full record

ArticleDermatology and therapy2017

Patients' Perspectives on the Impact of Genital Psoriasis: A Qualitative Study.

Jennifer Clay Cather, Caitriona Ryan, Kim Meeuwis, Alison J Potts Bleakman, April N Naegeli, Emily Edson-Heredia, Jiat Ling Poon, Cate Jones, Ashley N Wallace, Lyn Guenther and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jennifer Clay CatherModern Dermatology and Modern Research Associates, Dallas, TX, USA. jennifercather@mac.com.
Caitriona RyanDepartment of Dermatology, St Vincent's University Hospital, Dublin, Ireland.
Kim MeeuwisDepartments of Dermatology and Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands.
Alison J Potts BleakmanLilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN, USA.
April N NaegeliLilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN, USA.
Emily Edson-HerediaLilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN, USA.
Jiat Ling PoonEvidera, Bethesda, MD, USA.
Cate JonesLilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN, USA.
Ashley N WallaceDawes Fretzin Dermatology Group, Indianapolis, IN, USA.
Lyn GuentherThe Guenther Dermatology Research Centre, London, ON, Canada.
Scott FretzinDawes Fretzin Dermatology Group, Indianapolis, IN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPlaque psoriasis is a chronic skin disease where genital involvement is relatively common. Yet health care providers do not routinely evaluate psoriasis patients for genital involvement and patients do not readily initiate discussion of it.

methodsA qualitative study of 20 US patients with dermatologist-confirmed genital psoriasis (GenPs) and self-reported moderate-to-severe GenPs at screening was conducted to identify key GenPs symptoms and their impacts on health-related quality of life (HRQoL).

resultsPatients had a mean age of 45 years, 55% were female, and patients had high rates of current/recent moderate-to-severe overall (65%) and genital (70%) psoriasis. Patients reported the following GenPs symptoms: genital itch (100%), discomfort (100%), redness (95%), stinging/burning (95%), pain (85%), and scaling (75%). Genital itching (40%) and stinging/burning (40%) were the most bothersome symptoms. Impacts on sexual health included impaired sexual experience during sexual activity (80%), worsening of symptoms after sexual activity (80%), decreased frequency of sexual activity (80%), avoidance of sexual relationships (75%), and reduced sexual desire (55%). Negative effects on sexual experience encompassed physical effects such as mechanical friction, cracking, and pain as well as psychosocial effects such as embarrassment and feeling stigmatized. Males reported a higher burden of symptoms and sexual impacts. Other HRQoL impacts were on mood/emotion (95%), physical activities (70%), daily activities (60%), and relationships with friends and family (45%). These impacts significantly affected daily activities. Physical activities were affected by symptoms and flares, and increased sweat and friction worsened symptoms. Patients reported daily practices to control outcomes.

conclusionThe high level of reported symptoms and sexual and nonsexual impacts reflects the potential burden of moderate-to-severe GenPs. GenPs can impact many facets of HRQoL and providers should evaluate their patients for the presence of genital psoriasis and its impact on their quality of life.

fundingEli Lilly and Company.

Indexed as

Burden of illnessGenital psoriasisHealth-related quality of lifeQualitative research

Identifiers

PMID29076000
PMCPMC5698203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.